<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bisoprolol: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bisoprolol: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Bisoprolol: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11355" href="/d/html/11355.html" rel="external">see "Bisoprolol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866088"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AG-Bisoprolol;</li>
<li>APO-Bisoprolol;</li>
<li>JAMP-Bisoprolol;</li>
<li>MINT-Bisoprolol;</li>
<li>PMS-Bisoprolol [DSC];</li>
<li>PRO-Bisoprolol-10;</li>
<li>PRO-Bisoprolol-5;</li>
<li>RIVA-Bisoprolol [DSC];</li>
<li>SANDOZ Bisoprolol;</li>
<li>TEVA-Bisoprolol</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F141681"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antihypertensive;</li>
<li>
                        Beta-Blocker, Beta-1 Selective</li></ul></div>
<div class="block doa drugH1Div" id="F141641"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c263a8d4-f2ef-49a8-a963-6b87a475dbec">Angina</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angina (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For vasospastic angina, beta-blockers are not recommended; calcium channel blockers and nitrates are preferred. For nonvasospastic angina, guidelines recommend titrating dose to a resting heart rate of 55 to 60 beats per minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23166211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23166211'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 5 to 10 mg once daily; may increase dose after ≥1 week to achieve the desired effect to a maximum dose of 20 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1376806','lexi-content-ref-2568261','lexi-content-ref-7798508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1376806','lexi-content-ref-2568261','lexi-content-ref-7798508'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6086960c-10cb-4421-ba68-b5977a0bab8c">Atrial fibrillation/flutter, maintenance of ventricular rate control</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrial fibrillation/flutter, maintenance of ventricular rate control (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Initiate cautiously in patients with concomitant heart failure. Avoid initiating or up-titrating therapy in patients with decompensated heart failure; for unstable patients, electrical cardioversion is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24682347','lexi-content-ref-33081529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24682347','lexi-content-ref-33081529'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2.5 to 5 mg once daily; increase dose gradually as tolerated to achieve ventricular rate control up to 20 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24682347','lexi-content-ref-32860505','lexi-content-ref-35093388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24682347','lexi-content-ref-32860505','lexi-content-ref-35093388'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b43376ec-cceb-40f9-ad1e-9137f312af09">Heart failure with reduced ejection fraction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure with reduced ejection fraction (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Initiate only in stable, euvolemic patients. In hospitalized patients, volume status should be optimized and IV diuretics, IV vasodilators, and IV inotropic agents successfully discontinued prior to initiation of therapy. Use caution when initiating in patients with NYHA class IV symptoms or recent heart failure exacerbation (particularly if inotropes were required during hospital course) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 1.25 mg once daily; up-titrate gradually (eg, doubling the dose every ≥1 to 2 weeks) to a target dose of 10 mg once daily while monitoring for signs and symptoms of heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-10023943']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-10023943'])">Ref</a></span>). <b>Note:</b> A dose of 1.25 mg requires splitting a round 5 mg tablet into quarters in the United States and Canada, which may result in inaccurate dosing. Smaller tablet strengths are available in other countries.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Not recommended in the absence of specific comorbidities (eg, ischemic heart disease, heart failure with reduced ejection fraction, arrhythmia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2.5 to 5 mg once daily; titrate at weekly (or longer) intervals as needed based on patient response; usual dosage range: 2.5 to 10 mg once daily; maximum dose: 20 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2f42c553-e8c4-4b54-98fb-e270b999dc6b">Ventricular arrhythmias</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ventricular arrhythmias (off-</b>
<b>label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 2.5 mg once daily; titrate dose as needed based on response and tolerability up to a maximum dose of 10 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991495"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Bisoprolol has renal and hepatic clearance; total clearance in patients with severe kidney dysfunction (eg, CrCl &lt;20 mL/minute/1.73 m<sup>2</sup>) is decreased ~50% compared to those with normal kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2568209','lexi-content-ref-2887325','lexi-content-ref-2897297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2568209','lexi-content-ref-2887325','lexi-content-ref-2897297'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥20 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2887325','lexi-content-ref-2897297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2887325','lexi-content-ref-2897297'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;20 mL/minute/1.73 m<sup>2</sup>: Start with low initial doses (eg, 1.25 to 2.5 mg daily, depending on indication); consider a reduced maximum dose of 10 mg daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2887325','lexi-content-ref-2897297','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2887325','lexi-content-ref-2897297','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Moderately dialyzable (25% to 35%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10654875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10654875'])">Ref</a></span>): Initial: 1.25 to 2.5 mg daily, depending on indication; consider a reduced maximum dose of 10 mg daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2897297','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2897297','lexi-content-ref-Expert.DOR'])">Ref</a></span>). When scheduled dose falls on a hemodialysis day, administer dose after hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Slightly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2897297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2897297'])">Ref</a></span>): Initial 1.25 to 2.5 mg daily, depending on indication; consider a reduced maximum dose of 10 mg daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2897297','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2897297','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Initial 1.25 to 2.5 mg daily, depending on indication; consider a reduced maximum dose of 10 mg daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Initial 1.25 to 2.5 mg daily, depending on indication; consider a reduced maximum dose of 10 mg daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988857"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Hepatitis or cirrhosis: Initial: 2.5 mg once daily; increase cautiously.</p></div>
<div class="block doe drugH1Div" id="F141642"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F55780142"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bradyarrhythmias</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blockers may cause <b>first degree atrioventricular</b> (AV) <b>block</b>, <b>second degree atrioventricular block</b>, or <b>complete atrioventricular block</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15288162','lexi-content-ref-15234417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15288162','lexi-content-ref-15234417'])">Ref</a></span>). At maintenance dosing, second- or third-degree AV block are less likely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2450898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2450898'])">Ref</a></span>). Beta-blocking agents with intrinsic sympathomimetic activity (eg, pindolol) may cause fewer AV conduction abnormalities than those without intrinsic sympathomimetic activity (eg, bisoprolol) due to their partial agonist effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2903649','lexi-content-ref-1977302','lexi-content-ref-2450898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2903649','lexi-content-ref-1977302','lexi-content-ref-2450898'])">Ref</a></span>). In most cases (up to 72%), AV block associated with a beta-blocker will resolve upon discontinuation; however, there are reported cases of recurrent AV block and nearly 50% of patients with more severe AV block may require a permanent pacemaker (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22530749','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22530749','lexi-content-ref-32929996'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Blockade of cardiac beta-1 adrenergic receptors results in slowed conduction and prolongation in the refractory period of the AV node. Slowing of AV conduction can lead to AV block (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15288162','lexi-content-ref-2450898','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15288162','lexi-content-ref-2450898','lexi-content-ref-32929996'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; one study included patients who were on beta-blocker for more than one month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27899939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27899939'])">Ref</a></span>); however, other studies noted prolongation of the PR interval or AV nodal refractory period occurring anywhere from one dose to several days following treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2897302','lexi-content-ref-2450898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2897302','lexi-content-ref-2450898'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Impaired AV node or sinus node dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15288162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15288162'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other agents that impair AV nodal conduction (eg, nondihydropyridine calcium channel blockers, digoxin, ivabradine, select antiarrhythmic agents) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27899939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27899939'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27899939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27899939'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bronchospasm</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective beta-blockers (eg, bisoprolol) have a lower risk of <b>bronchospasm</b> compared to noncardioselective beta-blockers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27390282','lexi-content-ref-24202435','lexi-content-ref-6344309']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27390282','lexi-content-ref-24202435','lexi-content-ref-6344309'])">Ref</a></span>). Specifically, patients with moderate to severe asthma or COPD have a higher risk of symptoms or exacerbation leading to hospitalization even with selective beta-blocker use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31633896','lexi-content-ref-24202435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31633896','lexi-content-ref-24202435'])">Ref</a></span>). Concurrent use of inhaled bronchodilators and/or corticosteroids are protective against beta-blocker-induced bronchospasm in patients with COPD or asthma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12490274','lexi-content-ref-27390282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12490274','lexi-content-ref-27390282'])">Ref</a></span>). Bronchospasm is reversible upon discontinuation or use of bronchodilators (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2439802']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2439802'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to pharmacologic action. Beta-blocking agents can lead to airway smooth muscle constriction by antagonism of beta-2 receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27390282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27390282'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; reports suggest that single doses or acute use are more likely to cause changes in FEV<sub>1</sub> compared to chronic use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2439802','lexi-content-ref-24202435','lexi-content-ref-12519582']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2439802','lexi-content-ref-24202435','lexi-content-ref-12519582'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Acute use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24202435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24202435'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blockers may cause reversible CNS effects such as <b>fatigue</b>,<b> insomnia</b>, <b>vivid dreams</b>, <b>memory impairment</b>, and <b>sexual disorder</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22813717','lexi-content-ref-1969714','lexi-content-ref-12117400','lexi-content-ref-7807505','lexi-content-ref-1969642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22813717','lexi-content-ref-1969714','lexi-content-ref-12117400','lexi-content-ref-7807505','lexi-content-ref-1969642'])">Ref</a></span>). Sexual disorders may occur; however, patients who require beta-blocker therapy have risk factors for erectile dysfunction (eg, coronary artery disease, heart failure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29746858','lexi-content-ref-12117400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29746858','lexi-content-ref-12117400'])">Ref</a></span>). In addition, there may be a psychosomatic component (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18654082','lexi-content-ref-14585251']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18654082','lexi-content-ref-14585251'])">Ref</a></span>). Lipophilic beta-blockers (such as bisoprolol, which is moderately lipophilic) penetrate the blood-brain barrier to a greater extent than hydrophilic beta-blockers, possibly leading to a greater incidence of CNS effects; however, other studies have refuted this theory (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714','lexi-content-ref-1969642','lexi-content-ref-2865153']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714','lexi-content-ref-1969642','lexi-content-ref-2865153'])">Ref</a></span>). CNS effects generally resolve with dose reduction or discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; exact mechanism is not fully understood. Proposed mechanisms include presence of beta receptors in the brain, affinity and in some instances, inhibition of beta-blocking agents towards serotonin (5-HT) receptors in the brain (affecting mood and sleep), and beta-blocker-induced decreases in central sympathetic output (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8956349','lexi-content-ref-2865151','lexi-content-ref-2878741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8956349','lexi-content-ref-2865151','lexi-content-ref-2878741'])">Ref</a></span>). Beta-1 blockade may also impact sleep by blocking sympathetic signaling to the pineal gland, resulting in suppression of nighttime levels of melatonin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23024438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23024438'])">Ref</a></span>). Beta-blockers may cause erectile dysfunction through decreased sympathetic nervous system output and subsequent decreases in luteinizing hormone secretion and testosterone stimulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24155101']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24155101'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; CNS effects often occur within the first few weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher starting doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969642'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Potentiation/masking of hypoglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blockers may worsen, prolong, or cause hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31775749','lexi-content-ref-6376011','lexi-content-ref-2861072','lexi-content-ref-Vue.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31775749','lexi-content-ref-6376011','lexi-content-ref-2861072','lexi-content-ref-Vue.2011'])">Ref</a></span>). Additionally, beta-blockers may mask symptoms of hypoglycemia (tremor, irritability, palpitations), making diaphoresis the only symptom unaffected by beta-blockers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vue.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vue.2011'])">Ref</a></span>). It is unclear if nonselective or selective beta-blockers are more likely to cause hypoglycemia as data are conflicting. One study suggests bisoprolol has no effect on blood glucose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31775749','lexi-content-ref-20067434','lexi-content-ref-2439808','lexi-content-ref-85053','lexi-content-ref-6339540','lexi-content-ref-6376017','lexi-content-ref-Vue.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31775749','lexi-content-ref-20067434','lexi-content-ref-2439808','lexi-content-ref-85053','lexi-content-ref-6339540','lexi-content-ref-6376017','lexi-content-ref-Vue.2011'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to the pharmacologic action. Beta-blockers inhibit hepatic gluconeogenesis and glycogenolysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2861072','lexi-content-ref-Vue.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2861072','lexi-content-ref-Vue.2011'])">Ref</a></span>). Beta-blockers also reduce activation of the sympathetic nervous system; therefore, masking hypoglycemic symptoms that are catecholamine-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vue.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vue.2011'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied. Data are limited for bisoprolol; suggested that bisoprolol does not affect blood glucose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2439808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2439808'])">Ref</a></span>). Onset is extrapolated from other beta-blocking agents. Blood glucose recovery was significantly reduced following one dose or one day of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6376011','lexi-content-ref-85053','lexi-content-ref-6376017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6376011','lexi-content-ref-85053','lexi-content-ref-6376017'])">Ref</a></span>). In another study, episodes of severe hypoglycemia were reported over the course of 4 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28559400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28559400'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Insulin-dependent diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2861072']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2861072'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Type 2 diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28559400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28559400'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hospitalized patients not requiring basal insulin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31775749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31775749'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blocker therapy should not be withdrawn abruptly, but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia in patients with underlying cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2883874','lexi-content-ref-37093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2883874','lexi-content-ref-37093'])">Ref</a></span>). Some studies have found an increase in propensity-adjusted mortality and cardiovascular events; however, one study did not find changes in infarct size and left ventricular function when beta-blocker was abruptly withdrawn in patients with myocardial infarction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3009050','lexi-content-ref-18617067','lexi-content-ref-1968518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3009050','lexi-content-ref-18617067','lexi-content-ref-1968518'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-dependent; related to the pharmacologic action. Beta blockade causes upregulation of beta-receptors, enhanced receptor sensitivity, and decreased sympathetic nervous system response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2883874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2883874'])">Ref</a></span>). Abrupt withdrawal leads to a transient sympathetic hyper-response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2883874','lexi-content-ref-6125187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2883874','lexi-content-ref-6125187'])">Ref</a></span>). Another proposed mechanism involves increased platelet aggregability to epinephrine and thrombin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2883874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2883874'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid/varied and transient; increases in heart rate and blood pressure appear 24 hours after abrupt withdrawal, peak after 48 hours, and subside after 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37093'])">Ref</a></span>). Anginal symptoms reported to begin 12 to 24 hours after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1244260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1244260'])">Ref</a></span>). Development of adverse reactions also reported to occur 1 to 21 days after withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-668066']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-668066'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt withdrawal in chronic users (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37093'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Past medical history of coronary artery disease (including chronic stable angina) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2897781','lexi-content-ref-2883874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2897781','lexi-content-ref-2883874'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Past medical history of hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37093','lexi-content-ref-1968518','lexi-content-ref-6125187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37093','lexi-content-ref-1968518','lexi-content-ref-6125187'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F141605"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (3%), vomiting (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (7%)<span class="lexi-table-link-container"> (<a aria-label="Fatigue table link" class="lexi-table-link" data-table-id="lexi-content-fatigue" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fatigue')">table 1</a>)</span><span class="table-link" style="display:none;">Fatigue</span>, hypoesthesia (1%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fatigue" frame="border" id="lexi-content-fatigue" rules="all">
<caption style="text-align:center;">
<b>Bisoprolol: Adverse Reaction: Fatigue</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Bisoprolol)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Bisoprolol)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 mg to 20 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">273</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">132</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (1%), upper respiratory tract infection (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia, claudication, cold extremity, edema, flushing, heart failure, hypotension, orthostatic hypotension, palpitations</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, diaphoresis, eczema, pruritus, purpuric rash, skin irritation, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido, increased serum glucose, increased serum phosphate, increased serum potassium, increased serum triglycerides, increased uric acid, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, constipation, dysgeusia, dyspepsia, epigastric pain, gastritis, nausea, peptic ulcer, stomach pain, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis, sexual disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased white blood cell count, positive ANA titer, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity angiitis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, depression, dizziness, drowsiness, headache, hyperesthesia, lack of concentration, malaise, memory impairment, paresthesia, restlessness, tremor, twitching, vertigo, vivid dream</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain, gout, muscle cramps, myalgia, neck pain</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Abnormal lacrimation, eye pain, sensation of eye pressure, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine, polyuria, renal colic</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma, bronchitis, bronchospasm, cough, dyspnea on exertion, pharyngitis, rhinitis, sinusitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Complete atrioventricular block (Zeltser 2004), first-degree atrioventricular block (Zeltser 2004), second-degree atrioventricular block (Zeltser 2004), syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis, exacerbation of psoriasis (Waqar 2009), exfoliative dermatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Peyronie disease</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Insomnia (Chang 2013), sleep disturbance, unsteadiness</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory impairment</p></div>
<div class="block coi drugH1Div" id="F141619"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Cardiogenic shock; overt cardiac failure; marked sinus bradycardia or heart block greater than first-degree (except in patients with a functioning artificial pacemaker).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to bisoprolol or any component of the formulation; overt cardiac failure requiring IV inotropic therapy; sick sinus syndrome or sinoatrial block; hypotension (systolic BP &lt;100 mm Hg); severe bronchial asthma or chronic obstructive pulmonary disease; peripheral arterial occlusive disease (late stages); Raynaud syndrome; pheochromocytoma (untreated); metabolic acidosis.</p></div>
<div class="block war drugH1Div" id="F141602"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis reactions: Beta-blockers are unlikely to cause anaphylaxis; however, in susceptible patients, beta-blockers have been associated with an increase in the severity of anaphylaxis. Anaphylaxis in the presence of a beta-blocker may be severe, protracted, and resistant to conventional treatment (Lang 2008; Toogood 1987). This is due to beta-2-adrenergic blockade and the resulting diminution of endogenous catecholamine effect.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure with reduced ejection fraction: Stabilize patients on heart failure regimen prior to initiation or titration of beta-blocker. Beta-blocker therapy should be initiated at very low doses with gradual and careful titration. Worsening heart failure or fluid retention may occur during upward titration; dose reduction and/or slower titration may be necessary. Adjustment of other medications (ACE inhibitors and/or diuretics) may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution in patients with kidney impairment; dosage adjustment may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral vascular disease (PVD) and Raynaud disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud disease. Use with caution and monitor for progression of arterial obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If hyperthyroidism is suspected, carefully manage and monitor; abrupt withdrawal may precipitate thyroid storm.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vasospastic angina: Beta-blockers without alpha1-adrenergic receptor blocking activity should be avoided in patients with vasospastic angina since unopposed alpha1-adrenergic receptors mediate coronary vasoconstriction and can worsen anginal symptoms (Mayer 1998).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Dosage reductions may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abrupt withdrawal: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.</p></div>
<div class="block foc drugH1Div" id="F141613"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as fumarate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p></div>
<div class="block geq drugH1Div" id="F141598"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F141621"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Bisoprolol Fumarate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $1.40 - $2.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $1.40 - $2.25</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866089"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as fumarate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p></div>
<div class="block adm drugH1Div" id="F9460164"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> May be administered without regard to meals. The smallest tablet size available in the United States and Canada is 5 mg. A dose of 1.25 mg for heart failure with reduced ejection fraction would require splitting a round tablet into quarters.</p></div>
<div class="block use drugH1Div" id="F141616"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Hypertension:</b> Management of hypertension. <b>Note:</b> Beta-blockers are <b>not </b>recommended as first-line therapy (ACC/AHA [Whelton 2018]).</p></div>
<div class="block off-label drugH1Div" id="F25475209"><span class="drugH1">Use: Off-Label: Adult</span><p>Angina; Atrial fibrillation/flutter, maintenance of ventricular rate control; Heart failure with reduced ejection fraction; Ventricular arrhythmias</p></div>
<div class="block mst drugH1Div" id="F141689"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Zebeta may be confused with DiaBeta, Zetia</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F141674"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F141607"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Beta-Blockers (Beta1 Selective) may enhance the hypoglycemic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: Beta-Blockers may enhance the adverse/toxic effect of Cannabis. Specifically, the risk of hypoglycemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Bisoprolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Bisoprolol may increase the serum concentration of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOBUTamine: Beta-Blockers may diminish the therapeutic effect of DOBUTamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose. Increase monitoring for clinical response and adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPHEDrine (Systemic): Beta-Blockers may diminish the therapeutic effect of EPHEDrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Nasal): Beta-Blockers (Beta1 Selective) may diminish the therapeutic effect of EPINEPHrine (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Oral Inhalation): Beta-Blockers (Beta1 Selective) may diminish the therapeutic effect of EPINEPHrine (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Epinephrine (Racemic): Beta-Blockers (Beta1 Selective) may diminish the therapeutic effect of Epinephrine (Racemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Systemic): Beta-Blockers (Beta1 Selective) may diminish the therapeutic effect of EPINEPHrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may diminish the therapeutic effect of Etilefrine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etofylline: Beta-Blockers may diminish the therapeutic effect of Etofylline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grass Pollen Allergen Extract (5 Grass Extract): Beta-Blockers may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). More specifically, Beta-Blockers may inhibit the ability to effectively treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract) with epinephrine.  Some other effects of epinephrine may be unaffected or even enhanced (e.g., vasoconstriction) during treatment with Beta-Blockers.  Management: Consider alternatives to either grass pollen allergen extract (5 grass extract) or beta-blockers in patients with indications for both agents.  Canadian product labeling specifically lists this combination as contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoproterenol: Beta-Blockers may diminish the therapeutic effect of Isoproterenol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: Beta-Blockers may enhance the adverse/toxic effect of Mavacamten. Specifically, negative inotropic effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Beta-Blockers may enhance the therapeutic effect of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: May enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: May enhance the therapeutic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May diminish the therapeutic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Patiromer: May decrease the serum concentration of Bisoprolol. Management: Administer bisoprolol at least 3 hours before or 3 hours after patiromer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reserpine: May enhance the bradycardic effect of Beta-Blockers. Reserpine may enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: May enhance the bradycardic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Beta-Blockers may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: Beta-Blockers may diminish the therapeutic effect of Tasimelteon.  Management: Consider avoiding nighttime administration of beta-blockers during tasimelteon therapy due to the potential for reduced tasimelteon efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">White Birch Allergen Extract: Beta-Blockers may enhance the adverse/toxic effect of White Birch Allergen Extract. Specifically, beta-blockers may reduce the effectiveness of beta-agonists that may be required to treat systemic reactions to white birch allergen extract. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F58703596"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be continued in patients trying to conceive. Bisoprolol is generally not a preferred agent for use in pregnant patients (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019); however, use may be considered (ESC [Cífková 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Impotence is noted in product labeling following use of bisoprolol. As a class, outcomes from available studies evaluating beta-blockers and sexual dysfunction are inconsistent, and the negative effects on erectile function are considered controversial. A clear relationship between use of beta-blockers and erectile dysfunction has not been established. Hypertension itself is associated with erectile dysfunction. Patients on a beta-blocker presenting with sexual dysfunction should be evaluated for underlying disease (Farmakis 2022; Levine 2012; Semet 2017; Terentes-Printzios 2022; Viigimaa 2020).</p></div>
<div class="block pri drugH1Div" id="F141622"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome data following maternal use of bisoprolol during pregnancy are limited compared to other beta-1 selective beta-blockers (Hoeltzenbein 2018; Kayser 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Exposure to beta-blockers during pregnancy may increase the risk for adverse events in the neonate. If maternal use of a beta-blocker is needed, monitor fetal growth during pregnancy; monitor the newborn for 48 hours after delivery for bradycardia, hypoglycemia, and respiratory depression (ESC [Regitz-Zagrosek 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is also associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment of hypertension is initiated during pregnancy, agents other than bisoprolol may be preferred (ACOG 2019; ESC [Regitz-Zagrosek 2018]; SOGC [Magee 2022]); however, use of bisoprolol may be considered (ESC [Cífková 2020]).</p></div>
<div class="block brc drugH1Div" id="F10570481"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if bisoprolol is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Bisoprolol 5 mg/day was initiated in one patient 5 days postpartum. Bisoprolol was not detected in breast milk sampled 11 and 18 days later (lower limit of quantification 1 ng/mL) (Khurana 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends that caution be exercised when administering bisoprolol to breastfeeding patients. Use of a beta-blocker other than bisoprolol may be preferred in lactating patients (ESC [Cífková 2020]).</p></div>
<div class="block mop drugH1Div" id="F141611"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure, heart rate, ECG; serum glucose (in patients with diabetes); signs and symptoms of bronchospasm (in patients with preexisting bronchospastic disease); mental alertness.</p></div>
<div class="block rer drugH1Div" id="F57875367"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Blood pressure goal<b>:</b> May vary depending on clinical conditions, different clinical practice guidelines, and expert opinion. Refer to "Clinical Practice Guidelines" for specific treatment goals.</p></div>
<div class="block pha drugH1Div" id="F141601"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Selective inhibitor of beta<sub>1</sub>-adrenergic receptors; competitively blocks beta<sub>1</sub>-receptors, with little or no effect on beta<sub>2</sub>-receptors at doses ≤20 mg</p></div>
<div class="block phk drugH1Div" id="F141618"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid and almost complete</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely; highest concentrations in heart, liver, lungs, and saliva; crosses blood-brain barrier</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~30%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic; significant first-pass effect (~20%)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~80%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Normal kidney function: 9 to 12 hours; CrCl &lt;40 mL/minute: 27 to 36 hours; Hepatic cirrhosis: 8 to 22 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 2 to 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (50% as unchanged drug, remainder as inactive metabolites); feces (&lt;2%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F141624"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Biscor | Bisodac | Bisolol | Concor | Concor cor | Selecta</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Bicardil | Biprosol | Bisofec | Bisopil | Bisoprolol teva | Cardiplen | Concor | Corbis | Dromin | Etadiar | Lostaprolol | Problock</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Bilokord | Bisocor | Bisoprolol | Bisoprolol 1a Pharma | Bisoprolol Accord | Bisoprolol arcana | Bisoprolol sandoz | Concor | Rivacor</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo bisoprolol | Beprol | Bicard | Bicor | Biso | Bisoprolol | Bisoprolol an | Bisoprolol generichealth | Bisoprolol sandoz | Bispro | Chemmart Bisoprolol | Cipla bisoprolol | Noumed bisoprolol | Terry White Chemists Bisoprolol</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Acubis | Ancor | B prolol | Betabis | Betacor | Betafix | Bislol | Bisocor | Bisoloc | Bisopress | Bisopro | Bisoren | Bisotab | Bisu | Cardicor | Cardinor | Conbis | Concor | Diobis | Orabis | Prelizer | Probis | Sb bisop | Tenobis</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Bisoprolol apotex | Bisoprolol EG | Bisoprolol Eurogenerics | Bisoprolol merck-generics | Bisoprolol mylan | Bisoprolol ratiopharm | Bisoprolol sandoz | Bisoprolol teva generics belgium | Bisoprotop | Docbisopro | Emconcor | Isoten</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Bibloc | Biprol | Bisocon | Bisogamma | Bisolen | Bisoprolol Accord | Bisoprolol mylan | Bisor | Bisostad | Blokbis | Blokbis cor | Concor | Concor cor | Coronal | Kardoritm | Rizoprol | Sobycor | Tevabisoprol | Tyrez</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Concardio | Concor | Coraprol | Fumarato bisoprolol | Fumarato de bisoprolol | Hemifumarato de bisoprolol | Iccor</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Bilol | Bisoprolol actavis | Bisoprolol basan | Bisoprolol helvepharm | Bisoprolol mepha | Bisoprolol nobel | Bisoprolol sandoz | Bisoprolol spirig hc | Concor | Concor cor</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Bibloc | Bisoprolol</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Biprosel | Bisopril | Bisoprolol | Concor | Corentel | Eurocor | Tenbilol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bo su | Concor | Su lai le</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bisoprolol | Bisoprolol fumarato | Concor | Concor cor | Corbis | Zoprolol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Bisocard | Bisogamma | Bisoprolol | Bisoprolol aurovitas | Bisoprolol medreg | Bisoprolol mylan | Bisoprolol Orion | Bisoprolol pmcs | Bisoprolol vitabalans | Byol | Conaret | Concor | Concor cor | Rivocor | Sobycor | Tyrez</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Biso | Biso-puren | Bisobeta | Bisobloc | Bisogamma | Bisohexal | Bisolich | Bisomerck | Bisoprolol | Bisoprolol 1a Pharma | Bisoprolol Accord | Bisoprolol actavis | Bisoprolol al | Bisoprolol atid | Bisoprolol aurobindo | Bisoprolol awd | Bisoprolol axcount | Bisoprolol ct | Bisoprolol Dexcel | Bisoprolol Dura | Bisoprolol Heumann | Bisoprolol mylan | Bisoprolol puren | Bisoprolol ratiopharm | Bisoprolol sandoz | Bisoprolol stada | Bisoprolol tad | Bisoprolol teva | Bisoprolol Vem | Bisoprolol vitabalans | Bisoprolol-Corax | Bonfotin | Concor | Concor cor | Corocalm | Fondril | Jutabis</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Bisocor | Bisoprolol alpharma | Bisoprolol stada</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Betauno 10 | Betauno 2.5 | Betauno 5 | Bidicor | Biobloc | Biskrem | Bisocardil | Bisochem | Bisocor | Bisofel | Bisomax | Bisoprolol | Bisoprolol Alfa | Bisoprolol if | Bisoprolol Lam | Bisoprolol mk | Bisotab | Bloq | Cardibeta | Concor | Coradona | Coranprol | Corentel | Etablox | Eurobisop | Iberprodol | Linovo | Presolol | Prespol | Selecar MF | Solol</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Bisoprolol mk | Concardio | Concor | Corbis | Corentel | Eurocor</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Bisoprolol Accord | Bisoprolol vitabalans | Bisoprolol zentiva | Bisprotin | Concor | Concor cor | Sobycor</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Bisobeta | Bisocard | Bisolock | Bisoprol | Bistol | Concor | Concor cor | Egypro | Normocard | Soprol | Unibisol</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Bisoprolol aurovitas | Bisoprolol bluefish | Bisoprolol cinfa | Bisoprolol cor alter | Bisoprolol cor amneal | Bisoprolol Cor Apotex | Bisoprolol cor mylan | Bisoprolol cor sandoz | Bisoprolol edigen | Bisoprolol farmasierra | Bisoprolol kern | Bisoprolol krka | Bisoprolol mylan | Bisoprolol normon | Bisoprolol pensa | Bisoprolol ratiopharm | Bisoprolol sandoz | Bisoprolol stada | Bisoprolol Sumol | Bisoprolol zentiva | Emconcor | Emconcor cor | Euradal</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Bisoprolol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Bisomerck | Bisomyl | Bisopral | Bisoproact | Bisoprolol | Bisoprolol Accord | Bisoprolol krka | Bisoprolol mylan | Bisoprolol Orion | Bisoprolol pliva | Bisoprolol ratiopharm | Bisoprolol sandoz | Bisoprolol stada | Bisoprolol vitabalans | Bisoprololi Ennapharma | Bisprotin | Caraprol | Emconcor | Emconcor chf | Monocor | Orloc</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Bisoce | Bisoprolol Accord | Bisoprolol actavis | Bisoprolol Almus | Bisoprolol arrow | Bisoprolol Bgr | Bisoprolol biogaran | Bisoprolol crister | Bisoprolol Dci | Bisoprolol EG | Bisoprolol evolugen | Bisoprolol g gam | Bisoprolol gnr | Bisoprolol krka | Bisoprolol nor | Bisoprolol Qualimed | Bisoprolol quiver | Bisoprolol quiver lab | Bisoprolol ranbaxy | Bisoprolol ratiopharm | Bisoprolol ref | Bisoprolol rpg | Bisoprolol sandoz | Bisoprolol sun | Bisoprolol teva | Bisoprolol viatris | Bisoprolol zentiva | Bisoprolol Zentiva Lab | Bisoprolol zydus | Cardensiel | Cardiocor | Detensiel | Soprol</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Bipranix | Bisoprolol | Bisoprolol Almus | Bisoprolol arrow | Bisoprolol cox | Bisoprolol focus | Bisoprolol kent | Bisoprolol sandoz | Cardicor | Congescor | Emcor | Monocor | Rizoprol | Soloc | Vivacor</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Bisoprolol | Blocatens | Emconcor | Pactens | Theracor</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo bisoprolol | Bisoprolol stada | Bisostad | Concor | Nikp bisoprolol</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Biprol | Bisobel | Bisoprolol Pfizer | Byol | Byol Cor | Concor | Concor cor | Kordobis | Lybrol | Sobycor | Tyrez</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bisoblock | Bisocard | Bisogamma | Bisogen | Bisoprolol actavis | Bisoprolol hexal | Bisoprolol ratiopharm | Bisoprolol sandoz | Bisoprolol vitabalans | Bisotens | Concor | Concor cor | Coviogal | Sobycor</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">B beta | Beta one | Bipro | Biscor | Bisoprolol | Bisovell | Concor | Hapsen | Maintate | Tencard</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Bisocor | Bisop | Bisopine | Bisoprolol | Bisoprolol actavis | Bisoprolol krka | Bisoprolol mylan | Bisoprolol Niche | Cardicor | Emcolol | Emcor | Soprol</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Cardiloc | Concor</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acbiso | Besoloc | Bibeta | Biselect | Bisobis | Bisocar | Bisoheart | Bisokem | Bisolong | Bisonext | Bisopharm | Bisosafe | Bisotab | Bisveda | Concor | Corbis | Lonipress | Zabesta</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Bisoprololo | Bisoprololo aurobindo | Bisoprololo doc | Bisoprololo eg | Bisoprololo hexal | Bisoprololo krka | Bisoprololo mylan | Bisoprololo pensa | Bisoprololo Sandoz | Bisoprololo teva | Bisoprololo Winthrop | Bisoprololo zentiva | Cardicor | Concor | Congescor | Pluscor | Sequacor</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Biscor | Bisoprol | Cardicor | Concor | Concor cor | Forcicor | Promivol</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Azopsin | Azopsin chemiphar | Azopsin merck hoei | Bisoprolol | Bisoprolol fumarate meiji | Bisoprolol Fumarate Yoshindo | Bisotate | Luke | Luke merck hoei | Luke zensei | Main heart amel | Mainheart | Mainries | Mainrol | Maintate | Maintowa | Meitat | Metolomain | Metolomain alfresa | Pramatate | Seafuri | Well Bi</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Anginol | Bisocar | Bisocor | Bisodac hf | Bisolol | Bisopress | Bisoprolol | Bisotrol | Concor | Corbis</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Beta one | Betadren | Betaprol | Biprol | Bisohexal | Bisonal | Bisopol | Bisorol | Conbloc | Concor | Concrin | Congclean | Hemiprol | Monocor | Sandoz bisoprolol</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Bisoprol | Concor | Concor cor</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo bisoprolol | Biscordex | Bisocor | Bisohexal | Bisoprolol | Cardiosafe | Concor | Prescor</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Bisoprolol | Bisoprolol 1a Pharma | Bisoprolol actiofarma | Bisoprolol bijon | Bisoprolol fumarate zentiva | Bisopromerck | Bisprotin | Concor | Emconcor | Zonsiloc</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Bisoprolol EG | Bisoprolol Eurogenerics | Bisoprolol ratiopharm | Bisoprolol sandoz | Bisosandoz | Concor | Isoten</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Bisocard | Bisogamma | Bisoprolol Accord | Bisoprolol ratiopharm | Bisoprolol vitabalans | Bisoprolol zentiva | Bisprotin | Concor | Concor cor | Corbis | Coronal | Sobycor</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Bicardol | Biprol | Bisocard | Bisopral | Cardensiel | Detensiel | Soprol</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bisoprolol | Bisoprolol cor sandoz | Bitecral | Caurodol | Concor | Corebipro | Embicor | Loroprax | Sig | Vilopre</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Adroten | Bisloc | Bisocar | Bisocor | Bisodac hf | Bisohexal | Bisol | Concor | Hypercor | Tisderol | Vasoten</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Bisodac | Bisoprolol | Concor | Corbis</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Bisobloc | Bisoprolol-Fumaraat Actavis | Bisoprololfumaraat | Bisoprololfumaraat Accord | Bisoprololfumaraat aurobindo | Bisoprololfumaraat Gf | Bisoprololfumaraat PCH | Bisoprololfumaraat ratiopharm | Bisoprololfumaraat sandoz | Emconcor | Emcor</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Bisoprolol sandoz | Bisoprolol vitabalans | Emconcor | Emconcor chf | Stromolol</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Bisoprolol mylan | Bisoprolol viatris | Bosvate</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Biprol-5 | Bisoprolol | Bisopsi | Cardioprol | Combicor | Concor | Corbis | Corentel | Eurocor | Goxicardin | Lostaprolol | Novoblock | Seleblock</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Biscore | Bisoprolol sandoz | Bisosten | Concore</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Abcor | Actim | Actiprolol | Barilol | Beslol | Biscord | Biscot | Bisfat | Bisheart | Bisolol | Bison | Bisovel | Bisprol | Bpr | Concor | Corbis | Iprol | Lisoprolol | Monitor | Monocor | Probase | Safcor | Sopral | Valvozid | Vegaprol</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Antipres | Bibloc | Bicardef | Bicardiol | Bidop | Bilokord | Bisocard | Bisogamma | Bisohexal | Bisoprolol actavis | Bisoprolol aurobindo | Bisoprolol genoptim | Bisoprolol ozone | Bisoprolol vitabalans | Bisoprolol vp | Bisopromerck | Bisoratio | Conaret | Concor | Concor cor | Corectin | Coronal | Ripit | Sobycor</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Zebeta</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Bisoprol | Bisoprol aurovitas | Bisoprolol | Bisoprolol Accord | Bisoprolol aurobindo | Bisoprolol Germed | Bisoprolol gp | Bisoprolol itf | Bisoprolol krka | Bisoprolol mylan | Bisoprolol ratiopharm | Bisoprolol tolife | Bisoprolol zentiva | Concor</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Corentel | Eurocor | Lostaprolol | Novoblock</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">B-Cor | Biscor | Bisopress | Bisoprol | Cardex | Cardiosafe | Concor | Concor COR</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Bisoblock | Bisogamma | Bisoprolol fumarat aurobindo | Bisoprolol lph | Bisostad | Bisotens | Concor | Concor cor | Sobyc</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Aritel | Aritel Cor | Bidop | Bidop cor | Biol | Biprol | Biscard | Bisogamma | Bisomor | Bisoprolol | Bisoprolol canon | Bisoprolol leksvm | Bisoprolol lugal | Bisoprolol obl | Bisoprolol prana | Bisoprolol ratiopharm | Bisoprolol teva | Bisoproncor | Concor | Concor cor | Corbis | Cordinorm | Cordinorm cor | Coronal | Niperten | Tyrez</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">B Cor | Biscor | Bisolol | Bitrol | Cardex | Cardicor | Cardioprol | Concor | Concor cor | Pms bisoprolol | Selecta</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Bisocard | Bisomyl | Bisoprolol 2care4 | Bisoprolol abacus medicine | Bisoprolol abboxia | Bisoprolol Accord | Bisoprolol actavis | Bisoprolol ebb | Bisoprolol krka | Bisoprolol medical valley | Bisoprolol mylan | Bisoprolol orifarm | Bisoprolol Orion | Bisoprolol paranova | Bisoprolol ratiopharm | Bisoprolol sandoz | Bisoprolol stada | Bisoprolol teva | Bisoprolol vitabalans | Bisostad | Cardicor | Emconcor | Emconcor chf | Speridol</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Bisohexal | Blokbis | Concor</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Bisoblock | Borez | Byol | Concor | Concor cor | Sobycor</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Bisobela | Bisocard | Bisogamma | Bisomerck | Bisoprolol | Bisoprolol medreg | Bisoprolol Orion | Bisoprolol ozone | Bisoprolol sandoz | Bisoprolol vitabalans | Conaret | Concor | Coronal | Rivocor | Sobycor | Tyrez</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Betacor | Bisloc | Concor | Hypercor | Nikp bisoprolol | Novacor | Sopalol</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Biprocard | Bisocor | Bisopral | Bisotens | Bonacor | Cincor | Detensiel | Evocor | Soprol</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Concor | Kardoritm | Rizoprol | Soprano</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Betacor | Biocor | Biso | Bisocor | Bisol | Bistable | Biteven | Cidincor | Concor | Kenco | Monocor | Purcon | Sinbisol</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Bicard | Bidop | Biprolol | Bisocard | Bisoprolol | Bisoprolol apo | Bisoprolol astrafarm | Bisoprolol aurobindo | Bisoprolol hexal | Bisoprolol krka | Bisoprolol lugal | Bisoprolol ratiopharm | Bisoprolol richter | Bisoprolol sandoz | Bisoprolol teva | Bisoprolol zdorovje | Bisoprophar | Bisoprovel | Bisostad | Concor | Concor cor | Corbis | Cordinorm | Cordinorm cor | Coronal | Eurobisoprolol</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Bisoprolol | Concor | Corbis</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Bicardil | Corentel | Novoblock | Vontrol</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Algiol | Antaar | Bibloc | Biotalol | Biprocor | Biprolil | Bisobloc | Bisoprolol | Bisopruni | Concor | Coranprol | Corbis | Corentel | Prebloc | Probis | Tisderol</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Agicardi | Bihasal | Glocor | Haiblok | Maxxprolol | Misopato | Savi Prolol | Zentobiso</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco-Bisocor | Bilocor | Bisbeta | Bislo | Bisohexal | Bisoprolol 10 accord | Bisoprolol Accord | Bisoprolol hexal | Bisoprolol unichem | Bisoprolol Unicorn | Bisoprolol zydus | Cardicor | Concor | Mylan bisoprolol | Presicard | Retocar | Ziapro</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Bisohexal | Corbis</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Bilocor</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29084731">
<a name="29084731"></a>Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published online ahead of print October 30, 2017]. <i>Circulation</i>. 2017. doi:10.1161/CIR.0000000000000549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/29084731/pubmed" id="29084731" target="_blank">29084731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19926021">
<a name="19926021"></a>American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Rhythm Society; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine; Society for Vascular Surgery, Fleischmann KE, Beckman JA, Buller CE, et al. 2009 ACCF/AHA focused update on perioperative beta blockade [published correction appears in <i>J Am Coll Cardiol</i>. 2012;59(24):2306]. <i>J Am Coll Cardiol</i>. 2009;54(22):2102-2128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/19926021/pubmed" id="19926021" target="_blank">19926021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 203: Chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15358045">
<a name="15358045"></a>Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). <i>J Am Coll Cardiol</i>. 2004;44(3):671-719.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/15358045/pubmed" id="15358045" target="_blank">15358045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18191746">
<a name="18191746"></a>Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol</i>. 2008;51(2):210-249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/18191746/pubmed" id="18191746" target="_blank">18191746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17175824">
<a name="17175824"></a>Becker DE, Reed KL. Essentials of local anesthetic pharmacology. <i>Anesth Prog.</i> 2006;53(3):98-108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/17175824/pubmed" id="17175824" target="_blank">17175824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bisoprolol.1">
<a name="Bisoprolol.1"></a>Bisoprolol fumarate (bisoprolol) [prescribing information]. East Windsor, NJ: Novitium Pharma LLC; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bisoprolol.2">
<a name="Bisoprolol.2"></a>Bisoprolol [product monograph]. St-Laurent, Quebec, Canada: Sivem Pharmaceuticals ULC; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18410416">
<a name="18410416"></a>Brauchli YB, Jick SS, Curtin F, et al. Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study. <i>Br J Dermatol</i>. 2008;158(6):1299-1307.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/18410416/pubmed" id="18410416" target="_blank">18410416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29746858">
<a name="29746858"></a>Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA Guideline. <i>J Urol</i>. 2018;200(3):633-641. doi:10.1016/j.juro.2018.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/29746858/pubmed" id="29746858" target="_blank">29746858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22813717">
<a name="22813717"></a>Chang CH, Yang YH, Lin SJ, Su JJ, Cheng CL, Lin LJ. Risk of insomnia attributable to β-blockers in elderly patients with newly diagnosed hypertension. <i>Drug Metab Pharmacokinet</i>. 2013;28(1):53-58. doi:10.2133/dmpk.dmpk-12-rg-004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/22813717/pubmed" id="22813717" target="_blank">22813717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18654082">
<a name="18654082"></a>Cocco G. Erectile dysfunction after therapy with metoprolol: the Hawthorne effect. <i>Cardiology</i>. 2009;112(3):174-177. doi:10.1159/000147951<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/18654082/pubmed" id="18654082" target="_blank">18654082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3009050">
<a name="3009050"></a>Croft CH, Rude RE, Gustafson N, et al. Abrupt withdrawal of beta-blockade therapy in patients with myocardial infarction: effects on infarct size, left ventricular function, and hospital course. <i>Circulation</i>. 1986;73(6):1281-1290. doi:10.1161/01.cir.73.6.1281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/3009050/pubmed" id="3009050" target="_blank">3009050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1969714">
<a name="1969714"></a>Dahlöf C, Dimenäs E. Side effects of beta-blocker treatments as related to the central nervous system. <i>Am J Med Sci</i>. 1990;299(4):236-244. doi:10.1097/00000441-199004000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/1969714/pubmed" id="1969714" target="_blank">1969714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1376806">
<a name="1376806"></a>de Muinck ED, Buchner-Moell D, van de Ven LL, Lie KI. Comparison of the safety and efficacy of bisoprolol versus atenolol in stable exercise-induced angina pectoris: a Multicenter International Randomized Study of Angina Pectoris (MIRSA). <i>J Cardiovasc Pharmacol</i>. 1992;19(6):870-875. doi:10.1097/00005344-199206000-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/1376806/pubmed" id="1376806" target="_blank">1376806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31633896">
<a name="31633896"></a>Dransfield MT, Voelker H, Bhatt SP, et al; BLOCK COPD Trial Group. Metoprolol for the prevention of acute exacerbations of COPD. <i>N Engl J Med</i>. 2019;381(24):2304-2314. doi:10.1056/NEJMoa1908142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/31633896/pubmed" id="31633896" target="_blank">31633896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31775749">
<a name="31775749"></a>Dungan K, Merrill J, Long C, Binkley P. Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients. <i>Cardiovasc Diabetol</i>. 2019;18(1):163. doi:10.1186/s12933-019-0967-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/31775749/pubmed" id="31775749" target="_blank">31775749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2897781">
<a name="2897781"></a>Egstrup K. Transient myocardial ischemia after abrupt withdrawal of antianginal therapy in chronic stable angina. <i>Am J Cardiol</i>. 1988;61(15):1219-1222. doi:10.1016/0002-9149(88)91158-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/2897781/pubmed" id="2897781" target="_blank">2897781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33945044">
<a name="33945044"></a>Farmakis IT, Pyrgidis N, Doundoulakis I, Mykoniatis I, Akrivos E, Giannakoulas G. Effects of major antihypertensive drug classes on erectile function: a network meta-analysis. <i>Cardiovasc Drugs Ther</i>. 2022;36(5):903-914. doi:10.1007/s10557-021-07197-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/33945044/pubmed" id="33945044" target="_blank">33945044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>Circulation</i>, 2012;126(25):3097-3137. doi:10.1161/CIR.0b013e318277d6a0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18617067">
<a name="18617067"></a>Fonarow GC, Abraham WT, Albert NM, et al; OPTIMIZE-HF Investigators and Coordinators. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. <i>J Am Coll Cardiol</i>. 2008;52(3):190-199. doi:10.1016/j.jacc.2008.03.048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/18617067/pubmed" id="18617067" target="_blank">18617067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20067434">
<a name="20067434"></a>Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. <i>Curr Med Res Opin</i>. 2010;26(3):615-629. doi:10.1185/03007990903533681<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/20067434/pubmed" id="20067434" target="_blank">20067434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6867180">
<a name="6867180"></a>Foster CA, Aston SJ. Propranolol-Epinephrine Interaction: A Potential Disaster. <i>Plast Reconstr Surg</i>. 1983;72(1):74-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/6867180/pubmed" id="6867180" target="_blank">6867180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2883874">
<a name="2883874"></a>Frishman WH. Beta-adrenergic blocker withdrawal. <i>Am J Cardiol</i>. 1987;59(13):26F-32F. doi:10.1016/0002-9149(87)90038-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/2883874/pubmed" id="2883874" target="_blank">2883874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2903649">
<a name="2903649"></a>Frishman WH. Circulatory and metabolic aspects of beta-adrenoceptor blockade. <i>Am Heart J</i>. 1988;116(5 Pt 2):1393-1400. doi:10.1016/0002-8703(88)90129-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/2903649/pubmed" id="2903649" target="_blank">2903649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2910169">
<a name="2910169"></a>Gandy W. Severe epinephrine-propranolol interaction. <i>Ann Emerg Med.</i> 1989;18:98-99.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/2910169/pubmed" id="2910169" target="_blank">2910169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8956349">
<a name="8956349"></a>Gleiter CH, Deckert J. Adverse CNS-effects of beta-adrenoceptor blockers. <i>Pharmacopsychiatry</i>. 1996;29(6):201-211. doi:10.1055/s-2007-979572<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/8956349/pubmed" id="8956349" target="_blank">8956349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2568209">
<a name="2568209"></a>Grevel J, Thomas P, Whiting B. Population pharmacokinetic analysis of bisoprolol. <i>Clin Pharmacokinet</i>. 1989;17(1):53-63. doi:10.2165/00003088-198917010-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/2568209/pubmed" id="2568209" target="_blank">2568209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10085663">
<a name="10085663"></a>Haas DA. Adverse drug interactions in dental practice: interactions associated with analgesics, part III in a series. <i>J Am Dent Assoc.</i> 1999;130(3):397-407.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/10085663/pubmed" id="10085663" target="_blank">10085663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1244260">
<a name="1244260"></a>Harrison DC, Alderman EL. Editorial: Discontinuation of propranolol therapy. Cause of rebound angina pectoris and acute coronary events. <i>Chest</i>. 1976;69(1):1-2. doi:10.1378/chest.69.1.1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/1244260/pubmed" id="1244260" target="_blank">1244260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064600">
<a name="22064600"></a>Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2011;124(23):2610-2642.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/22064600/pubmed" id="22064600" target="_blank">22064600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32860505">
<a name="32860505"></a>Hindricks G, Potpara T, Dagres N, et al; ESC Scientific Document Group. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. <i>Eur Heart J</i>. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/32860505/pubmed" id="32860505" target="_blank">32860505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29985206">
<a name="29985206"></a>Hoeltzenbein M, Fietz AK, Kayser A, et al. Pregnancy outcome after first trimester exposure to bisoprolol: an observational cohort study. <i>J Hypertens</i>. 2018;36(10):2109-2117. doi:10.1097/HJH.0000000000001818<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/29985206/pubmed" id="29985206" target="_blank">29985206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17506224">
<a name="17506224"></a>Huffman JC, Stern TA. Neuropsychiatric consequences of cardiovascular medications. <i>Dialogues Clin Neurosci</i>. 2007;9(1):29-45. doi:10.31887/DCNS.2007.9.1/jchuffman<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/17506224/pubmed" id="17506224" target="_blank">17506224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1977302">
<a name="1977302"></a>Jaillon P. Relevance of intrinsic sympathomimetic activity for beta blockers. <i>Am J Cardiol</i>. 1990;66(9):21C-23C. doi:10.1016/0002-9149(90)90758-s<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/1977302/pubmed" id="1977302" target="_blank">1977302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bisoprolol.3">
<a name="Bisoprolol.3"></a>JAMP Bisoprolol (bisoprolol fumarate, USP) [product monograph]. Boucherville, Quebec, Canada: JAMP Pharma Corporation; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2439808">
<a name="2439808"></a>Janka HU, Ziegler AG, Disselhoff G, Mehnert H. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. <i>J Cardiovasc Pharmacol</i>. 1986;8 suppl 11:S96-S99. doi:10.1097/00005344-198511001-00018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/2439808/pubmed" id="2439808" target="_blank">2439808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30703530">
<a name="30703530"></a>January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Heart Rhythm</i>. 2019. pii: S1547-5271(19)30037-2. doi: 10.1016/j.hrthm.2019.01.024.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/30703530/pubmed" id="30703530" target="_blank">30703530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682347">
<a name="24682347"></a>January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/24682347/pubmed" id="24682347" target="_blank">24682347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10654875">
<a name="10654875"></a>Kanegae K, Hiroshige K, Suda T, et al. Pharmacokinetics of bisoprolol and its effect on dialysis refractory hypertension. <i>Int J Artif Organs</i>. 1999;22(12):798-804.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/10654875/pubmed" id="10654875" target="_blank">10654875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31584512">
<a name="31584512"></a>Kayser A, Beck E, Hoeltzenbein M, et al. Neonatal effects of intrauterine metoprolol/bisoprolol exposure during the second and third trimester: a cohort study with two comparison groups. <i>J Hypertens</i>. 2020;38(2):354-361. doi:10.1097/HJH.0000000000002256<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/31584512/pubmed" id="31584512" target="_blank">31584512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24482268">
<a name="24482268"></a>Khurana R, Bin Jardan YA, Wilkie J, Brocks DR. Breast milk concentrations of amiodarone, desethylamiodarone, and bisoprolol following short-term drug exposure: two case reports. <i>J Clin Pharmacol</i>. 2014;54(7):828-831. doi:10.1002/jcph.272<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/24482268/pubmed" id="24482268" target="_blank">24482268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2887325">
<a name="2887325"></a>Kirch W, Rose I, Demers HG, Leopold G, Pabst J, Ohnhaus EE. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.<i> Clin Pharmacokinet</i>. 1987;13(2):110-117. doi:10.2165/00003088-198713020-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/2887325/pubmed" id="2887325" target="_blank">2887325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6376011">
<a name="6376011"></a>Kleinbaum J, Shamoon H. Effect of propranolol on delayed glucose recovery after insulin-induced hypoglycemia in normal and diabetic subjects. <i>Diabetes Care</i>. 1984;7(2):155-162. doi:10.2337/diacare.7.2.155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/6376011/pubmed" id="6376011" target="_blank">6376011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12117400">
<a name="12117400"></a>Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. <i>JAMA</i>. 2002;288(3):351-357. doi:10.1001/jama.288.3.351<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/12117400/pubmed" id="12117400" target="_blank">12117400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2865151">
<a name="2865151"></a>Koella WP. CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action. <i>Eur J Clin Pharmacol</i>. 1985;28(suppl):55-63. doi:10.1007/BF00543711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/2865151/pubmed" id="2865151" target="_blank">2865151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2878741">
<a name="2878741"></a>Kostis JB, Rosen RC. Central nervous system effects of beta-adrenergic-blocking drugs: the role of ancillary properties. <i>Circulation</i>. 1987;75(1):204-212. doi:10.1161/01.cir.75.1.204<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/2878741/pubmed" id="2878741" target="_blank">2878741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12490274">
<a name="12490274"></a>Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. <i>J Heart Lung Transplant</i>. 2002;21(12):1290-1295. doi:10.1016/s1053-2498(02)00459-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/12490274/pubmed" id="12490274" target="_blank">12490274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7807505">
<a name="7807505"></a>Kuriyama S. Bisoprolol-induced nightmares. <i>J Hum Hypertens</i>. 1994;8(9):730.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/7807505/pubmed" id="7807505" target="_blank">7807505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-85053">
<a name="85053"></a>Lager I, Blohmé G, Smith U. Effect of cardioselective and non-selective beta-blockade on the hypoglycaemic response in insulin-dependent diabetics. <i>Lancet</i>. 1979;1(8114):458-462. doi:10.1016/s0140-6736(79)90821-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/85053/pubmed" id="85053" target="_blank">85053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2439802">
<a name="2439802"></a>Lammers JW, Folgering HT, van Herwaarden CL. Respiratory tolerance of bisoprolol and metoprolol in asthmatic patients. <i>J Cardiovasc Pharmacol</i>. 1986;8(suppl 11):S69-S73. doi:10.1097/00005344-198511001-00012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/2439802/pubmed" id="2439802" target="_blank">2439802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7669259">
<a name="7669259"></a>Lang DM. Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers. <i>Drug Saf</i>. 1995;12(5):299-304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/7669259/pubmed" id="7669259" target="_blank">7669259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18377773">
<a name="18377773"></a>Lang DM. Do beta-blockers really enhance the risk of anaphylaxis during immunotherapy? <i>Curr Allergy Asthma Rep</i>. 2008;8(1):37-44. doi:10.1007/s11882-008-0008-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/18377773/pubmed" id="18377773" target="_blank">18377773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6339540">
<a name="6339540"></a>Lauridsen UB, Christensen NJ, Lyngsøe J. Effects of nonselective and beta-1-selective blockade on glucose metabolism and hormone responses during insulin-induced hypoglycemia in normal man. <i>J Clin Endocrinol Metab</i>. 1983;56(5):876-882. doi:10.1210/jcem-56-5-876<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/6339540/pubmed" id="6339540" target="_blank">6339540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37093">
<a name="37093"></a>Lederballe Pedersen O, Mikkelsen E, Lanng Nielsen J, Christensen NJ. Abrupt withdrawal of beta-blocking agents in patients with arterial hypertension. Effect on blood pressure, heart rate and plasma catecholamines and prolactin. <i>Eur J Clin Pharmacol</i>. 1979;15(3):215-217. doi:10.1007/BF00563108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/37093/pubmed" id="37093" target="_blank">37093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22267844">
<a name="22267844"></a>Levine GN, Steinke EE, Bakaeen FG, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Quality of Care and Outcomes Research. Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2012;125(8):1058-1072. doi:10.1161/CIR.0b013e3182447787<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/22267844/pubmed" id="22267844" target="_blank">22267844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6695818">
<a name="6695818"></a>Lewis GP, Holtzman JL. Interaction of flecainide with digoxin and propranolol. <i>Am J Cardiol</i>. 1984;53(5):52B-57B. doi:10.1016/0002-9149(84)90502-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/6695818/pubmed" id="6695818" target="_blank">6695818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16049209">
<a name="16049209"></a>Lindenauer PK, Pekow P, Wang K, et al. Perioperative Beta-Blocker Therapy and Mortality After Major Noncardiac Surgery. <i>N Engl J Med</i>. 2005;353(4):349-361.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/16049209/pubmed" id="16049209" target="_blank">16049209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27390282">
<a name="27390282"></a>Lipworth B, Wedzicha J, Devereux G, Vestbo J, Dransfield MT. Beta-blockers in COPD: time for reappraisal. <i>Eur Respir J</i>. 2016;48(3):880-888. doi:10.1183/13993003.01847-2015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/27390282/pubmed" id="27390282" target="_blank">27390282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28182127">
<a name="28182127"></a>Liu X, Lou X, Cheng X, Meng Y. Impact of metoprolol treatment on mental status of chronic heart failure patients with neuropsychiatric disorders. <i>Drug Des Devel Ther</i>. 2017;11:305-312. doi:10.2147/DDDT.S124497<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/28182127/pubmed" id="28182127" target="_blank">28182127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15288162">
<a name="15288162"></a>López-Sendón J, Swedberg K, McMurray J, et al; Task ForceOn Beta-Blockers of the European Society of Cardiology. Expert consensus document on beta-adrenergic receptor blockers. <i>Eur Heart J</i>. 2004;25(15):1341-1362. doi:10.1016/j.ehj.2004.06.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/15288162/pubmed" id="15288162" target="_blank">15288162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27899939">
<a name="27899939"></a>Lu HT, Kam J, Nordin RB, et al. Beta-blocker use and risk of symptomatic bradyarrhythmias: a hospital-based case-control study. <i>J Geriatr Cardiol</i>. 2016;13(9):749-759. doi:10.11909/j.issn.1671-5411.2016.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/27899939/pubmed" id="27899939" target="_blank">27899939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. <i>J Obstet Gynaecol Can</i>. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2568261">
<a name="2568261"></a>Maisch B, Borst U, Gerhards W, Wagner G. Effect of bisoprolol on cardiac performance in coronary heart disease. <i>Eur J Clin Pharmacol</i>. 1989;36(3):217-222. doi:10.1007/BF00558150<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/2568261/pubmed" id="2568261" target="_blank">2568261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9562933">
<a name="9562933"></a>Mayer S, Hillis LD. Prinzmetal's variant angina. <i>Clin Cardiol</i>. 1998;21(4):243-246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/9562933/pubmed" id="9562933" target="_blank">9562933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1969642">
<a name="1969642"></a>McAinsh J, Cruickshank JM. Beta-blockers and central nervous system side effects. <i>Pharmacol Ther</i>. 1990;46(2):163-197. doi:10.1016/0163-7258(90)90092-g<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/1969642/pubmed" id="1969642" target="_blank">1969642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2861072">
<a name="2861072"></a>Mills GA, Horn JR. Beta-blockers and glucose control. <i>Drug Intell Clin Pharm</i>. 1985;19(4):246-251. doi:10.1177/106002808501900401<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/2861072/pubmed" id="2861072" target="_blank">2861072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3278028">
<a name="3278028"></a>Mito RS, Yagiela JA. Hypertensive response to levonordefrin in a patient receiving propranolol: report of a case. <i>J Am Dent Assoc.</i> 1988;116(1):55-57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/3278028/pubmed" id="3278028" target="_blank">3278028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24202435">
<a name="24202435"></a>Morales DR, Jackson C, Lipworth BJ, Donnan PT, Guthrie B. Adverse respiratory effect of acute β-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. <i>Chest</i>. 2014;145(4):779-786. doi:10.1378/chest.13-1235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/24202435/pubmed" id="24202435" target="_blank">24202435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35093388">
<a name="35093388"></a>Muresan L, Cismaru G, Muresan C, et al. Beta-blockers for the treatment of arrhythmias: bisoprolol - a systematic review. <i>Ann Pharm Fr</i>. 2022;80(5):617-634. doi:10.1016/j.pharma.2022.01.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/35093388/pubmed" id="35093388" target="_blank">35093388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286277">
<a name="15286277"></a>National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. <i>Pediatrics</i>. 2004;114(2)(suppl):555-576.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/15286277/pubmed" id="15286277" target="_blank">15286277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286277">
<a name="15286277"></a>National Institute for Health and Care Excellence (NICE). NICE guideline: hypertension in pregnancy: diagnosis and management. http://www.nice.org.uk/guidance/ng133/. Updated June 25, 2019. Accessed December 1, 2022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/15286277/pubmed" id="15286277" target="_blank">15286277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24155101">
<a name="24155101"></a>Nicolai MP, Liem SS, Both S, et al. A review of the positive and negative effects of cardiovascular drugs on sexual function: a proposed table for use in clinical practice. <i>Neth Heart J</i>. 2014;22(1):11-19. doi:10.1007/s12471-013-0482-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/24155101/pubmed" id="24155101" target="_blank">24155101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29766868">
<a name="29766868"></a>Nikolaidou T, Ghosh JM, Clark AL. Outcomes related to first-degree atrioventricular block and therapeutic implications in patients with heart failure. <i>JACC Clin Electrophysiol</i>. 2016;2(2):181-192. doi:10.1016/j.jacep.2016.02.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/29766868/pubmed" id="29766868" target="_blank">29766868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24589852">
<a name="24589852"></a>Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/24589852/pubmed" id="24589852" target="_blank">24589852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22530749">
<a name="22530749"></a>Osmonov D, Erdinler I, Ozcan KS, et al. Management of patients with drug-induced atrioventricular block. <i>Pacing Clin Electrophysiol</i>. 2012;35(7):804-810. doi:10.1111/j.1540-8159.2012.03410.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/22530749/pubmed" id="22530749" target="_blank">22530749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081529">
<a name="33081529"></a>Panchal AR, Bartos JA, Cabañas JG, et al; Adult Basic and Advanced Life Support Writing Group. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16)(suppl 2):S366-S468. doi:10.1161/CIR.0000000000000916<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/33081529/pubmed" id="33081529" target="_blank">33081529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6344309">
<a name="6344309"></a>Patakas D, Argiropoulou V, Louridas G, Tsara V. Beta-blockers in bronchial asthma: effect of propranolol and pindolol on large and small airways. <i>Thorax</i>. 1983;38(2):108-112. doi:10.1136/thx.38.2.108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/6344309/pubmed" id="6344309" target="_blank">6344309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2897297">
<a name="2897297"></a>Payton CD, Fox JG, Pauleau NF, et al. The single dose pharmacokinetics of bisoprolol (10 mg) in renal insufficiency: the clinical significance of balanced clearance. <i>Eur Heart J</i>. 1987;8(suppl M):15-22. doi:10.1093/eurheartj/8.suppl_m.15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/2897297/pubmed" id="2897297" target="_blank">2897297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6376017">
<a name="6376017"></a>Popp DA, Tse TF, Shah SD, Clutter WE, Cryer PE. Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus. <i>Diabetes Care</i>. 1984;7(3):243-247. doi:10.2337/diacare.7.3.243<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/6376017/pubmed" id="6376017" target="_blank">6376017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2897302">
<a name="2897302"></a>Proclemer A, Gradnik R, Savonitto S, Feruglio GA. Electrophysiological effects of bisoprolol. <i>Eur Heart J</i>. 1987;8 Suppl M:81-85. doi:10.1093/eurheartj/8.suppl_m.81<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/2897302/pubmed" id="2897302" target="_blank">2897302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2450898">
<a name="2450898"></a>Prystowsky EN. The effects of slow channel blockers and beta blockers on atrioventricular nodal conduction. <i>J Clin Pharmacol</i>. 1988;28(1):6-21. doi:10.1002/j.1552-4604.1988.tb03095.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/2450898/pubmed" id="2450898" target="_blank">2450898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1968518">
<a name="1968518"></a>Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. <i>JAMA</i>. 1990;263(12):1653-1657.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/1968518/pubmed" id="1968518" target="_blank">1968518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6125187">
<a name="6125187"></a>Rangno RE, Langlois S. Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol. <i>Br J Clin Pharmacol</i>. 1982;13(suppl 2):345S-351S. doi:10.1111/j.1365-2125.1982.tb01939.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/6125187/pubmed" id="6125187" target="_blank">6125187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25840695">
<a name="25840695"></a>Rosendorff C, Lackland DT, Allison M, et al; American Heart Association; American College of Cardiology; and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-498.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/25840695/pubmed" id="25840695" target="_blank">25840695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12519582">
<a name="12519582"></a>Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for reversible airway disease. <i>Cochrane Database Syst Rev</i>. 2002;(4):CD002992. doi:10.1002/14651858.CD002992<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/12519582/pubmed" id="12519582" target="_blank">12519582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bisoprolol.4">
<a name="Bisoprolol.4"></a>Sandoz Bisoprolol tablets [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23024438">
<a name="23024438"></a>Scheer FA, Morris CJ, Garcia JI, et al. Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial. <i>Sleep</i>. 2012;35(10):1395-1402. doi:10.5665/sleep.2122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/23024438/pubmed" id="23024438" target="_blank">23024438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15872205">
<a name="15872205"></a>Schön MP, Boehncke WH. Psoriasis. <i>N Eng J Med</i>. 2005;352(18):1899-1912.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/15872205/pubmed" id="15872205" target="_blank">15872205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28622464">
<a name="28622464"></a>Semet M, Paci M, Saïas-Magnan J, et al. The impact of drugs on male fertility: a review. <i>Andrology</i>. 2017;5(4):640-663. doi:10.1111/andr.12366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/28622464/pubmed" id="28622464" target="_blank">28622464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-668066">
<a name="668066"></a>Shand DG, Wood AJ. Propranolol withdrawal syndrome - why? <i>Circulation</i>. 1978;58(2):202-223. doi:10.1161/01.cir.58.2.202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/668066/pubmed" id="668066" target="_blank">668066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14585251">
<a name="14585251"></a>Silvestri A, Galetta P, Cerquetani E, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. <i>Eur Heart J</i>. 2003;24(21):1928-1932. doi:10.1016/j.ehj.2003.08.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/14585251/pubmed" id="14585251" target="_blank">14585251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20675664">
<a name="20675664"></a>Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. <i>Eur J Heart Fail</i>. 2010;12(8):767-778.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/20675664/pubmed" id="20675664" target="_blank">20675664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22052934">
<a name="22052934"></a>Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation. <i>Circulation</i>. 2011;124(22):2458-2473.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/22052934/pubmed" id="22052934" target="_blank">22052934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-947574">
<a name="947574"></a>Strauss HC, Gilbert M, Svenson RH, Miller HC, Wallace AG. Electrophysiologic effects of propranolol on sinus node function in patients with sinus node dysfunction. <i>Circulation</i>. 1976;54(3):452-459. doi:10.1161/01.cir.54.3.452<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/947574/pubmed" id="947574" target="_blank">947574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34331033">
<a name="34331033"></a>Terentes-Printzios D, Ioakeimidis N, Rokkas K, Vlachopoulos C. Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs. <i>Nat Rev Cardiol</i>. 2022;19(1):59-74. doi:10.1038/s41569-021-00593-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/34331033/pubmed" id="34331033" target="_blank">34331033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10023943">
<a name="10023943"></a>The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. <i>Lancet</i>. 1999;353(9146):9-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/10023943/pubmed" id="10023943" target="_blank">10023943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias: A scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2882832">
<a name="2882832"></a>Toogood JH. Beta-blocker therapy and the risk of anaphylaxis. <i>CMAJ</i>. 1987;136(9):929-933.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/2882832/pubmed" id="2882832" target="_blank">2882832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28559400">
<a name="28559400"></a>Tsujimoto T, Sugiyama T, Shapiro MF, Noda M, Kajio H. Risk of cardiovascular events in patients with diabetes mellitus on β-blockers. <i>Hypertension</i>. 2017;70(1):103-110. doi:10.1161/HYPERTENSIONAHA.117.09259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/28559400/pubmed" id="28559400" target="_blank">28559400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11527128">
<a name="11527128"></a>Verrostte JM, van Hemel NM, Kingma JH. Interaction of bisoprolol and procainamide in human cardiac impulse generation and conduction. <i>J Cardiovasc Pharmacol</i>. 1990;16(suppl 5):S193-S195.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/11527128/pubmed" id="11527128" target="_blank">11527128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32073535">
<a name="32073535"></a>Viigimaa M, Vlachopoulos C, Doumas M, et al; European Society of Hypertension Working Group on Sexual Dysfunction. Update of the position paper on arterial hypertension and erectile dysfunction. <i>J Hypertens</i>. 2020;38(7):1220-1234. doi:10.1097/HJH.0000000000002382<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/32073535/pubmed" id="32073535" target="_blank">32073535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7798508">
<a name="7798508"></a>von Arnim T. Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators. <i>J Am Coll Cardiol</i>. 1995;25(1):231-238. doi:10.1016/0735-1097(94)00345-q<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/7798508/pubmed" id="7798508" target="_blank">7798508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vue.2011">
<a name="Vue.2011"></a>Vue MH, Setter SM. Drug-induced glucose alterations part 1: Drug-induced hypoglycemia. <i>Diabetes Spectrum</i>. 2011;24(3):171-177. doi.org/10.2337/diaspect.24.3.171</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19581619">
<a name="19581619"></a>Waqar S, Sarkar PK. Exacerbation of psoriasis with beta-blocker therapy. <i>CMAJ</i>. 2009;181(1-2):60. doi:10.1503/cmaj.081433<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/19581619/pubmed" id="19581619" target="_blank">19581619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2865153">
<a name="2865153"></a>Westerlund A. Central nervous system side-effects with hydrophilic and lipophilic beta-blockers. <i>Eur J Clin Pharmacol</i>. 1985;28(suppl):73-76. doi:10.1007/BF00543714.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/2865153/pubmed" id="2865153" target="_blank">2865153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. <i>Hypertension</i>. 2018;71(6):e13-e115. doi:10.1161/HYP.0000000000000065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2871333">
<a name="2871333"></a>Wong DG, Spence JD, Lamki L, et al. Effect of Nonsteroidal Anti-inflammatory Drugs on Control of Hypertension of Beta-Blockers and Diuretics. <i>Lancet</i>. 1986;1(8488):997-1001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/2871333/pubmed" id="2871333" target="_blank">2871333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7911769">
<a name="7911769"></a>Wynn RL. Epinephrine Interactions With Beta-Blockers. <i>Gen Dent</i>. 1994;42(1):16, 18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/7911769/pubmed" id="7911769" target="_blank">7911769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15234417">
<a name="15234417"></a>Zeltser D, Justo D, Halkin A, et al. Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug. <i>J Am Coll Cardiol</i>. 2004;44(1):105-108. doi:10.1016/j.jacc.2004.03.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bisoprolol-drug-information/abstract-text/15234417/pubmed" id="15234417" target="_blank">15234417</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9158 Version 455.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
